STARPHARMA HOLDINGS LIMITED (SPL)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
SPL - STARPHARMA HOLDINGS LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.36
Index: ALL-ORDS
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.13
06 Dec |
OPEN $0.14 |
HIGH $0.14 |
782,041 LOW $0.13 |
-0.005| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -3.8 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 2.9 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 8.5 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -13.5 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -532.09 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -37.59 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -33.47 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -26.45 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -37.59 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -49.51 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -14.2 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 6 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 3 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 8 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 35 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 3.66 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.6 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 21.13 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 2 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 26 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 19 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
SPL STOCK CHART
FNArena News on SPL
| 1 |
Australian Broker Call *Extra* Edition – Nov 14, 2022Nov 14 2022 - Daily Market Reports |
| 2 |
Australian Broker Call *Extra* Edition – Sep 14, 2022Sep 14 2022 - Daily Market Reports |
| 3 |
Rudi’s View: August Results – First BloodAug 11 2022 - Rudi's View |
| 4 |
August In Review: Eleventh Month Of GainsSep 10 2021 - Australia |
| 5 |
February In Review: ASX Rises Five Consecutive MonthsMar 04 2021 - Australia |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
| 2 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
| 3 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
| 4 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |
| 5 |
Breaking Boundaries: Medical PsychedelicsAug 21 2023 - Small Caps |
| 6 |
Momentum Keeps Building For Avita MedicalAug 15 2023 - Small Caps |
| 7 |
Dr Boreham’s Crucible: IDT AustraliaAug 14 2023 - Small Caps |
| 8 |
Treasure Chest: Less Smooth Road Ahead For CSLAug 01 2023 - Treasure Chest |
| 9 |
Dr Boreham’s Crucible: Telix PharmaceuticalsJul 31 2023 - Small Caps |
| 10 |
Dr Boreham’s Crucible: Arovella TherapeuticsJul 17 2023 - Small Caps |
